- AIG Board OKs CEO Pay; Benmosche Agrees to Stay
- Obama Reiterates Commitment to Boost US-India Ties
- FDIC's Bair Cautions on Risks in Bank Break-Up Plan
- Wednesday's Economic News Crunch Could Tilt Markets
- Call Me Crazy: Confessions of a Black Friday Shopper
- 'Very Blah' Christmas Is Coming for UK Retailers
- US Firms Hit by Payroll Taxes at Exactly the Wrong Time
- Citi Mortgage Reveals Something the US Treasury Won't
- In Time for Holidays: More Gloom and Doom on Economy
- Citi Mortgage Reveals What Treasury Won't
- S&P to Hit 1,200 by Year-End: Chief Investor
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- Facebook's Biggest-Ever Holiday Shopping Season
- Facebook's New Dual Class Structure - Slow Steps to an IPO
- 5 Big Bank Stocks Investors Should Consider: Strategists
- Gambling Drunk, Texting to Live And America's On Sale - Your Emails
- Nov. 24: Unusual Volume Leaders
- NBA D-League On The Rise
MOST SHARED
- Wednesday's Economic News Crunch Could Tilt Markets
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- The Social Media Gaming Threat
- NBA D-League On The Rise
- Obama Reiterates Commitment to Boost US-India Ties
- Stifling Anger at Work Can Kill, Survey Finds
- Australia Wheat Exporters Face Challenges: GrainCorp
- Japan Export Rebound Eases Fear of New Recession
Text Size 
A new study shows that a diabetes treatment awaiting FDA approval may also work as a weight loss drug.
 |
AP |
Obese patients who took various doses of the one-a-day injectable Victoza from Novo Nordisk [NVO
Loading...
()
] lost between 10 and 14 pounds.
That compares to nine pounds shed by clinical trial participants who took the prescription diet pill Xenical from Roche [RHHBY
Loading...
()
], which is also sold without a prescription by GlaxoSmithKline [GSK
Loading...
()
] in lower doses under the brand name Alli. The results are in the new issue of the British medical journal "The Lancet."
In addition, three out of four patients who got Victoza lost at least 5 percent of their body weight. And it cut the prevalence of so-called prediabetes by 84-96 percent.
The FDA is deciding whether to approve Victoza as a diabetes treatment. It would compete with a similar drug Byetta from Eli Lilly [LLY
Loading...
()
] and Amylin Pharmaceuticals [AMLN
Loading...
()
].
Researchers say longer-term studies need to be done on Victoza in the obese population, but this study shows its potential as an "important" treatment for obese prediabetics.
A Novo spokesperson did not provide a comment on the study.
Print
Email
- Remember when auto shows were major events where new models could generate buzz?
- CNBC’s Mike Huckman visits a cutting-edge plant to see how the flu vaccine of the future is being made.
- People who bottle up their anger at work are up to five times more likely to suffer a heart attack, a study found.
- Playboy will outsource its publishing operations in a bid to become profitable again.
- A new McDonald's in Manhattan is the nation's first to sport a sleek, chic interior imported from stores in London and Paris.
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
Data is a real-time snapshot *Data is delayed at least 15 minutes